JP2019515676A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515676A5
JP2019515676A5 JP2018555460A JP2018555460A JP2019515676A5 JP 2019515676 A5 JP2019515676 A5 JP 2019515676A5 JP 2018555460 A JP2018555460 A JP 2018555460A JP 2018555460 A JP2018555460 A JP 2018555460A JP 2019515676 A5 JP2019515676 A5 JP 2019515676A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
alk7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018555460A
Other languages
English (en)
Japanese (ja)
Other versions
JP7103950B2 (ja
JP2019515676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/028952 external-priority patent/WO2017185037A1/en
Publication of JP2019515676A publication Critical patent/JP2019515676A/ja
Publication of JP2019515676A5 publication Critical patent/JP2019515676A5/ja
Application granted granted Critical
Publication of JP7103950B2 publication Critical patent/JP7103950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018555460A 2016-04-22 2017-04-21 Alk7結合性タンパク質及びその使用 Active JP7103950B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326313P 2016-04-22 2016-04-22
US62/326,313 2016-04-22
PCT/US2017/028952 WO2017185037A1 (en) 2016-04-22 2017-04-21 Alk7 binding proteins and uses thereof

Publications (3)

Publication Number Publication Date
JP2019515676A JP2019515676A (ja) 2019-06-13
JP2019515676A5 true JP2019515676A5 (enExample) 2020-06-11
JP7103950B2 JP7103950B2 (ja) 2022-07-20

Family

ID=60089402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018555460A Active JP7103950B2 (ja) 2016-04-22 2017-04-21 Alk7結合性タンパク質及びその使用

Country Status (8)

Country Link
US (4) US10501547B2 (enExample)
EP (1) EP3445394A4 (enExample)
JP (1) JP7103950B2 (enExample)
KR (2) KR20220080015A (enExample)
CN (3) CN109219446B (enExample)
AU (1) AU2017252574B2 (enExample)
CA (1) CA3018272A1 (enExample)
WO (1) WO2017185037A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3413912A4 (en) 2016-02-11 2019-09-25 The Johns Hopkins University COMPOSITIONS AND METHODS FOR TARGETING ACTIVIN SIGNALING FOR THE TREATMENT OF CANCER
JP7103950B2 (ja) 2016-04-22 2022-07-20 アクセレロン ファーマ インコーポレーテッド Alk7結合性タンパク質及びその使用
EP3694545A4 (en) 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
BR112020007751A2 (pt) * 2017-10-25 2020-10-20 Acceleron Pharma Inc. proteínas de ligação de alk7 e usos das mesmas
US11976128B2 (en) 2018-03-23 2024-05-07 Board Of Regents, The University Of Texas System Human PD-L2 antibodies and methods of use therefor
EP4501355A3 (en) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
EP3768723A4 (en) 2018-03-23 2021-12-29 Board of Regents, The University of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
KR20220016136A (ko) * 2019-05-30 2022-02-08 악셀레론 파마 인코포레이티드 Alk7 결합 단백질 및 이의 용도
EP4217378A4 (en) * 2020-10-08 2025-02-26 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
EP4531891A4 (en) * 2022-05-27 2026-08-12 Univ Johns Hopkins ACTIVINE SIGNALING ACTIVITY

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6790938B1 (en) * 1997-06-06 2004-09-14 Asat Ag Applied Science & Technology Anti-GPIIb/IIIa recombinant antibodies
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
KR20060019587A (ko) 2003-06-11 2006-03-03 머크 앤드 캄파니 인코포레이티드 치환된 3-알킬 및 3-알케닐 아제티딘 유도체
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
CN101287764B (zh) * 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
NZ623273A (en) * 2008-12-05 2015-09-25 Abraxis Bioscience Llc Sparc binding scfvs
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGENBINDING MOLECULE FOR PREPARING A SPACE BETWEEN A PLASMA AND AN ANTIGEN WITH A SACCHARIDE CHAIN RECEPTOR BINDING DOMAIN
US9783614B2 (en) 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
EP3517545A1 (en) * 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂,其制备方法和用途
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
BR112016014163A2 (pt) 2013-12-19 2018-01-09 Arsanis Biosciences Gmbh anticorpos direcionados contra a toxina lukgh (lukab) de staphylococcus aureus e as sequências de anticorpos, seu uso no tratamento ou no diagnóstico de infecção por s. aureus, as preparações farmacêuticas e para diagnóstico, os ácidos nucleicos que codificam os anticorpos, o paratopo isolado dos anticorpos e o epítopo conformacional isolado
KR101644043B1 (ko) 2014-03-18 2016-08-01 한국과학기술원 Rna에 특이적으로 결합하는 항체
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
JP7103950B2 (ja) 2016-04-22 2022-07-20 アクセレロン ファーマ インコーポレーテッド Alk7結合性タンパク質及びその使用
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
BR112020007751A2 (pt) 2017-10-25 2020-10-20 Acceleron Pharma Inc. proteínas de ligação de alk7 e usos das mesmas

Similar Documents

Publication Publication Date Title
JP2024026159A5 (enExample)
JP2021500895A5 (enExample)
JP2019513015A5 (enExample)
JP7103950B2 (ja) Alk7結合性タンパク質及びその使用
JP2022534966A5 (enExample)
JP2021527714A (ja) 抗pd−1抗体及びその使用
CN109311971A (zh) 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途
JP2010043089A5 (enExample)
AU2010229705A1 (en) Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
JP2022534514A5 (enExample)
WO2013147212A1 (ja) 新規抗Siglec-15抗体
JP2013503626A (ja) グルカゴン受容体に対する抗体と、それらの使用
WO2013147213A1 (ja) CDR改変抗Siglec-15抗体
IL295979A (en) Anti-cd36 antibodies and their use to treat cancer
CA3192208A1 (en) Anti-par-2 antibodies and methods of use thereof
JP7698635B2 (ja) 抗幹細胞因子抗体及びその使用方法
WO2017088782A1 (zh) 抗pcsk9抗体及其应用
KR20200096223A (ko) Ildr2 길항제 및 그의 조합물
JP7617036B2 (ja) Alk7結合タンパク質及びその使用
JP7510208B2 (ja) 抗TrkA抗体又はその抗原結合フラグメント、その調製方法及び使用
TW201012476A (en) Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers
RU2652880C2 (ru) Антитело против рецептора эпидермального фактора роста
JP2024505987A (ja) 抗tnfr2抗体およびその使用
JP7756686B2 (ja) ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
WO2021058735A1 (en) Cancer treatment with anti-met antibody compositions